Moderna’s third quarter was marked by robust revenue growth, operational improvements, and a positive market response. Management attributed the strong results to higher-than-anticipated sales of COVID-19 vaccines, effective international expansion, and disciplined cost management. CEO Stéphane Bancel highlighted the successful launch of the mFLUSIVA influenza vaccine in the U.S. and Canada, along with positive phase III data for the company’s individualized cancer therapy, intismeran. The quarter also saw Moderna strengthen its financial position through a convertible debt financing and welcome back Juan Andres to its executive committee, reflecting a focus on expanding both its commercial and manufacturing capabilities.

Is now the time to buy MRNA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Moderna’s Q3 earnings call

• Salveen Richter (Goldman Sachs) asked about confidence in the renal cell carcinoma interim data and the LNP’s role in immunogenicity; Chief Development Officer David Berman explained the rationale for optimism, citing prior melanoma results and overlapping tumor biology, but noted the statistical analysis remains data-driven.

• Terence Flynn (Morgan Stanley) pressed for pricing considerations of intismeran and whether phase II RCC data could support registration; President Stephen Hoge said pricing will reflect value but remains undecided, while Berman indicated phase II results could inform practice but would require strong data for regulatory filing.

• Ellie Merle (Barclays) inquired about next steps in pancreatic cancer and disclosure plans for RCC study outcomes; Berman said combination strategies are under review with Merck, and disclosure timing for RCC is yet to be determined.

• Alec Stranahan (Bank of America) questioned the depth of data at the upcoming ASH meeting for mRNA-2808 and whether 2026 growth guidance reflected shipment timing; Berman indicated more patient data and follow-up will be presented, while CFO Jamey Mock confirmed growth was broad-based, not timing-related.

• Courtney Breen (Bernstein) asked about efficacy signals in early pancreatic cancer data and durability of international revenue; Berman cautioned that efficacy interpretation is premature, and Mock described international growth as durable, driven by long-term strategic partnerships.

Catalysts in upcoming quarters

In the quarters ahead, the StockStory team will be watching (1) progress on regulatory submissions and launches for new respiratory vaccines, (2) the timing and outcomes of phase II and III oncology trial readouts—particularly in renal cell carcinoma, lung cancer, and rare diseases, and (3) further international expansion and execution of strategic partnerships. Sustained cost efficiencies and cash management will also be critical for tracking Moderna’s ability to reinvest in pipeline growth.

Moderna currently trades at $256.75, up from $241.46 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

The best stocks for high-quality investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.